Video

Stefan Bornstein, MD: Adherence Concerns for Diabetic Patients

Author(s):

Amputations have increased 30% among diabetic patients since the pandemic began.

Outside of the risk of contracting the coronavirus disease 2019 (COVID-19), many clinicians are concerned over whether patients with type 2 diabetes are adhering to their treatment regimens during the ongoing pandemic.

While the risk for severe outcomes is elevated in these patients and are vulnerable to mortality from the virus, a lack of medical adherence is also a concern.

In an interview with HCPLive®, Stefan Bornstein, MD, Professor of Endocrinology, Metabolism, and Diabetes at the Technical University at Dresden, said limb amputations for patients with type 2 diabetes have increased by 30% in just a few months.

Bornstein said this increase is largely attributed to a decrease in medication adherence.

He also explained once vaccines are widely available, diabetic patients should be considered a high-risk group and be given priority for the available vaccinations.

Recently, Bornstein presented new data during the 18th World Congress of Insulin Resistance Diabetes & Cardiovascular (WCIRDC) Online CME Conference, sponsored by the Metabolic Institute of America (TMIOA).

Bornstein’s presentation focuses on the severity of the viral infections and hyperglycemia and uncontrolled diabetes. He explained it is still unknown why there is such an association between this patient population and COVID-19 outcomes.

Related Videos
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Safety Data on Dupilumab, Ensifentrine for COPD, with MeiLan Han, MD
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
© 2024 MJH Life Sciences

All rights reserved.